Skip to main content

Minimally Invasive Gastrointestinal Surgical Systems Market is anticipated to reach $10,441.0 million by 2031

 The global minimally invasive gastrointestinal surgical systems market was valued at $5,021.8 million in 2020 and is anticipated to reach $10,441.0 million by 2031, growing at a CAGR of 6.8% during the forecast period 2021-2031. 

Factors that can boost the growth of the market include advantages of minimally invasive surgical procedures over conventional open surgical procedures, availability of technological advanced products in the field of GI surgical procedures, increasing healthcare spending, and growth in robotics GI surgical procedures.

Surgeries for which minimally invasive gastrointestinal surgical systems can be used include Adrenalectomy, Appendectomy, Bariatric Surgery, Cholecystectomy, Colon and Rectal Surgery, Foregut Surgery, and Hernia Repair. End-users that use minimally invasive gastrointestinal surgical systems include hospitals, ambulatory surgical centers, and specialty clinics.

Key players operating in the market include Ambu A/S, B. Braun Melsungen AG, Boston Scientific Corporation, Conmed Corporation, Cook Medical Inc., Intuitive Surgical, Inc., Olympus Corporation, Medtronic plc, Karl Storz SE & Co. KG, Stryker Corporation, Schölly Fiberoptic GmbH, Xenocor Inc., Fujifilm Holdings Corporation, Pentax Medical (Hoya Corporation), Richard Wolf GmbH, and TransEnterix, Inc.

Growth Drivers

•    Advantages of Minimally Invasive Surgical Procedures Over Conventional Open Surgical Procedures

•    Availability of Technological Advanced Products in the Field of GI Surgical Procedures

•    Increasing Healthcare Spending

•    Growth in Robotics GI Surgical Procedures


Market Challenges

•    High Cost of Minimally Invasive GI Surgical Procedures

•    Shortage of Skilled Professionals

•    Restrictive Reimbursement Framework


Market Opportunities

•    Development of Long-Distance Teleoperated Surgical Robotic Systems

•     Mergers and Acquisitions to Diversify Endoscopic Portfolio

•    Investment for Regional Expansion

Key Questions Answered in this Report:

•    What is the current market size and future potential of these products?
•    What is the current market share and growth share of the different products in the market?
•    What are the guidelines implemented by different government bodies to regulate the approval of minimally invasive gastrointestinal surgical systems?
•    What are the major market drivers, restraints, and opportunities in the global minimally invasive gastrointestinal surgical systems market?
•    What is the impact of the COVID-19 pandemic on the market?
•    Which technology is being researched and worked upon to improve the gastrointestinal surgical systems?
•    Who are the leading players dominating the global minimally invasive gastrointestinal surgical systems market?
•    What are the key development and strategies incorporated by the players of global minimally invasive gastrointestinal surgical systems market, to sustain the competition and retain their supremacy?
•    Which countries contribute to the major share of current demand and which countries hold significant scope for expansion for business activities, by players of the global minimally invasive gastrointestinal surgical systems market?
•    How advanced technologies such as surgical robotics is gaining traction in terms of market share in in gastrointestinal space?

Request a Sample - https://bisresearch.com/requestsample?id=1072&type=download







Labels:

Comments

Post a Comment

Popular posts from this blog

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

  Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing   microbiome therapeutics market    is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...
Post a Comment
Read more

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

  The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global  ligase market  is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.   Impact Several techniques are employed in ...
Post a Comment
Read more

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

  PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market   are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...
Post a Comment
Read more